Publications

33. Jackson PA, Widen JC, Harki DA* and Brummond KM*. Covalent modifiers: A chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-Michael addition reactions. J. Med. Chem. In press.

32. Richards CM, Li M, Perkins AL, Rathore A, Harki DA and Harris RS*. Reassessing APOBEC3G inhibition by HIV-1 Vif-derived peptides. J. Mol. Biol. In press[PDF]

31. Widen JC, Kempema, AM, Villalta, PW and Harki DA*. Targeting NF-kappaB p65 with a helenalin inspired bis-electrophile. ACS Chem. Biol. In press. [PDF] - [Supporting Information]

30. Wells SM, Widen JC, Harki DA* and Brummond KM*. Alkyne ligation handles: Propargylation of hydroxyl, sulfhydryl, amino, and carboxyl groups via the Nicholas reaction. Org. Lett. 2016, 18, 4566-4569[PDF] - [Supporting Information]

29. Breunig SL, Olson ME, and Harki DA*. Rapid, microwave accelerated synthesis of [1,2,4]triazolo[3,4-b][1,3,4]oxadiazoles from 4-acylamino-1,2,4-triazoles. Tetrahedron Lett. 2016, 57, 4056-4060. [PDF] - [Supporting Information]

28.  Perkins AL, Peterson KL, Beito TG, Flatten KS, Kaufmann SH and Harki DA*. Synthesis of a peptide-universal nucleotide antigen: Towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes. Org. Biomol. Chem. 2016, 14, 4103-4109. [PDF] - [Supporting Information]

27.  Struntz NB and Harki DA*. Catch & release DNA decoys: Capture and photochemical dissociation of NF-kappaB transcription factors. ACS Chem. Biol2016, 11, 1631-1638. [PDF] - [Supporting Information]

Highlight on Nick Struntz: Introducing Our Authors - ACS Chemical Biology.

26.  Patel AG, Flatten KS, Peterson KL, Beito TG, Schneider PA, Perkins AL, Harki DA, Kaufmann SH*. Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res. 2016, 44, 2816-2826. [PDF] - [Supporting Information]

25.  Richards C, Albin JS, Demir Ö, Shaban NM, Luengas EM, Land AM, Anderson BD, Holten JR, Anderson JS, Harki DA, Amaro RE, and Harris RS*. The binding interface between human APOBEC3F and HIV-1 Vif elucidated by genetic and computational approaches. Cell Rep. 2015, 13, 1781-1788. [PDF] - [Supporting Information]

24.  Kerr JP, Robinson P, Shi G, Bogush AI, Kempema AM, Hexum JK, Becerra N, Harki DA, Martin SS, Ratieri R, Prosser BLand Ward CW*. Detyrosinated microtubules modulate mechanotransduction in heart and skeletal muscle. Nat. Commun. 2015, 6, 8526. [PDF] - [Supporting Information] 

23.  Olson ME, Abate-Pella D, Perkins AL, Li M, Carpenter MA, Rathore A, Harris RS and Harki DA*. Oxidative reactivities of 2-furylquinolines: Ubiquitous scaffolds in common high-throughput screening libraries. J. Med. Chem. 201558, 7419-7430. [PDF] - [Supporting Information]

Commentary: False Positives Are Always Waiting - In the Pipeline (Derek Lowe).

22.  Kempema AM, Widen JC, Hexum JK, Andrews TW, Wang D, Rathe SK, Meece FA, Noble K, Sachs Z, Largaespada DA and Harki DA*. Synthesis and antileukemic activities of C1-C10 modified parthenolide analogues. Bioorg. Med. Chem. 2015, 23, 4737-4745. [PDF] - [Supporting Information]

21.  Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA and Harki DA*. Parthenolide prodrug LC-1 slows growth of intracranial glioma. Bioorg. Med. Chem. Lett. 201525, 2493-2495. [PDF] - [Supporting Information]

20.  Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA and Dehm SM*. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget 2015, 6, 3811-3824[PDF] - [Supporting Information]

19.  Wen B, Hexum JK, Widen JC, Harki DA* and Brummond KM*. A redox economical synthesis of bioactive 6,12-guaianolides. Org. Lett. 2013, 15, 2644-2647. [PDF] - [Supporting Information]

18.  Andrews TE, Wang D, and Harki DA*. Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery (invited review). Drug Deliv. Transl. Res. 2013, 3, 121-142. [PDF]

17.  Olson ME, Li M, Harris RS and Harki DA*. Small molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem 2013, 8, 112-117. [PDF] - [Supporting Information]

 

Article featured on the ChemMedChem cover [PDF]

 

 

16.  Struntz NB, Hu T, White BR, Olson ME, and Harki DA*. Inhibition of guanosine monophosphate synthetase by the substrate enantiomer L-XMP. ChemBioChem 2012, 13, 2517-2520. [PDF] - [Supporting Information]

15.  Hexum JK, Tello-Aburto R, Struntz NB, Harned AM*, and Harki DA*. Bicyclic cyclohexenones as inhibitors of NF-kappaB signaling. ACS Med. Chem. Lett. 2012, 3, 459-464. [PDF] - [Supporting Information]

14.  Li M, Shandilya SMD, Carpenter MA, Rathore A, Brown WL, Perkins AL, Harki DA, Solberg J, Hook DJ, Johnson JR, Krogan NJ, Somasundaran M, Ali A, Schiffer CA, and Harris RS*. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 2012, 7, 506-517. [PDF] - [Supporting Information]

For manuscripts listed above: † = co-first authors; * = corresponding author.


From Professor Harki's postdoctoral, graduate, and undergraduate research:

13.  Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda K, Wheeler J, Harki DA, Muzikar KA, Stolper DA, Dervan PB, and Perkins AS. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry 2011, 50, 10431-10441.

12.  Chenoweth DM, Harki DA, and Dervan PB. Oligomerization route to Py-Im polyamide macrocycles. Org. Lett. 2009, 11, 3590-3593.

11.  Chenoweth DM, Harki DA, Phillips JW, Dose C, and Dervan PB. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J. Am. Chem. Soc. 2009, 131, 7182-7188.

10.  Chenoweth DM, Harki DA, and Dervan PB. Solution-phase synthesis of pyrrole-imidazole polyamides. J. Am. Chem. Soc. 2009, 131, 7175-7181.

9.  Harki DA, Satyamurthy N, Stout DB, Phelps ME, and Dervan PB. In vivo imaging of pyrrole-imidazole polyamides with positron emission tomography. Proc. Natl. Acad. Sci. USA 2008, 105, 13039-13044.

8.  Zamyatkin DF, Parra F, Martín Alonso JM, Harki DA, Peterson BR, Grochulski P, and Ng KKS. Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase. J. Biol. Chem. 2008, 283, 7705-7712.

7.  Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger Jr. JM, Peterson BR, Loakes D, Brown DM, and Cameron CE. Lethal mutagenesis of picornaviruses with N6-modified purine nucleoside analogues. Antimicrob. Agents Chemother. 2008, 52, 971-979.

6.  Graci JD, Harki DA, Korneeva VS, Edathil JP, Too K, Franco D, Smidansky ED, Paul AV, Peterson BR, Brown DM, Loakes D, and Cameron CE. Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J. Virol. 2007, 81, 11256-11266.

5.  Harki DA, Graci JD, Edathil JP, Castro C, Cameron CE, and Peterson BR. Synthesis of a universal 5-nitroindole ribonucleotide and incorporation into RNA by a viral RNA-dependent RNA polymerase. ChemBioChem 2007, 8, 1359-1362.

4.  Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, and Peterson BR. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J. Med. Chem. 2006, 49, 6166-6169.

3.  Simeonova PP, Hulderman T, Harki D, Luster MI. Arsenic exposure accelerates atherogenesis in apolipoprotein E-/- mice. Environ. Health Perspect. 2003, 111, 1744-1748.

2.  Harki DA, Graci JD, Korneeva VS, Ghosh SKB, Hong Z, Cameron CE, and Peterson BR. Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-β-D-ribofuranosyl-3-nitropyrrole. Biochemistry 2002, 41, 9026-9033.

1.  Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Harki D, Ding M, Vallyathan V, Luster MI. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res. 2000, 60, 3445-3453.